Project Grant H79TI086770
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $823,809 to the University of Pittsburgh to develop and validate a suite of multidimensional measures of access to Medications for Opioid Use Disorder (MOUD) across U.S. states and the District of Columbia. The primary objectives are to: Create a Small Area Multidimensional MOUD Access (SAMMA) measure suite using public data sources. Validate and...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $752,184 to the University of Massachusetts Medical School (UMMS) to address challenges in collaboration between drug courts and medication-assisted treatment (MOUD) providers. The project, titled "Improving Access to MOUD in Drug Courts Through Inter-Agency Collaboration: COLAAB Study," aims to adapt, implement, and evaluate a...
- The U.S. Centers for Disease Control and Prevention (CDC), through the Injury Prevention and Control Research and State and Community Based Programs (CFDA 93.136), awarded a $449,998 Cooperative Agreement to the University of Pennsylvania to support the "PRAGMATIC IMPLEMENTATION OF STRATEGIC INTERVENTIONS TO IMPROVE INITIATION OF MOUD WITHIN EMERGENCY DEPARTMENTS." The project aims to develop and implement effective practices for preventing injuries and violence, with a focus on...
- This $683,222 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) aims to analyze access to medications to treat opioid use disorder (OUD) among Medicare beneficiaries. The study will assess disparities in access to medication-assisted treatment (MOUD) and evaluate the impact of state and federal policies on MOUD utilization and health outcomes. Key areas of focus include examining how provider quality contributes to MOUD access disparities, as well as...
- This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) totaling $945,397 provides funding to the Magee-Womens Research Institute and Foundation, with a sub-award to the University of Pittsburgh, to adapt and evaluate a collaborative care model (CCM) for treating pregnant persons with opioid use disorder (OUD) in low-resource obstetric settings. The key objectives are to: 1) adapt the CCM for rural and low-resource...
- The National Institute on Drug Abuse (NIDA), under CFDA Program 93.279 - Drug Use and Addiction Research Programs, awarded a $1,548,605 Project Grant to the University of Massachusetts Medical School (UMMS) to test the effectiveness of the Jail ECHO Operations, Planning, and Strategy (J-ECHO OPS) implementation strategy to increase access to Medication for Opioid Use Disorder (MOUD) in rural jails. The study, titled "Improving Jail Response to the Overdose Crisis: A Hybrid Trial of Jail...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), is focused on evaluating the impact of state policies that facilitate the initiation of medication-based treatment for opioid use disorder (OUD) in emergency department settings. The $794,574 grant will fund a 5-year project to: 1) create a public database of state laws related to emergency department-based initiation of medications for OUD treatment; 2) analyze national...
- This Project Grant award of $722,917 from the National Institute on Drug Abuse (NIDA), part of the Department of Health and Human Services, will fund a 5-year study to evaluate a new approach for dispensing methadone to incarcerated individuals with opioid use disorder (OUD) in three state prison systems. The project aims to support widespread implementation of the hospital/clinic designation, which allows carceral facilities to stock and dispense methadone for OUD treatment, by launching a...
- The National Institute on Drug Abuse (NIDA) awarded a 4.75-year, $1,541,502 Project Grant to Oregon Health & Science University (OHSU) under the Drug Use and Addiction Research Programs (CFDA 93.279) to study the impact of telehealth expansion on opioid use disorder (OUD) care delivery within community health centers. The project aims to evaluate patterns of telephone, video, and in-person visits for OUD treatment and identify multi-level characteristics associated with the use of each...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports a 5-year, $187,164 research project at Temple University to study the impact of Medicaid "Institutions for Mental Diseases" (IMD) waivers on the utilization of medications for opioid use disorder (MOUD) treatment. The key objectives are to: 1) characterize IMD waiver features across jurisdictions to enable comparison, 2) measure the...
PROVIDERS CLINICAL SUPPORT SYSTEM- MEDICATIONS FOR OPIOID USE DISORDERS - PROJECT ABSTRACT SUMMARY: PCSS-MOUD OPIOID RELATED OVERDOSES CONTINUE AT UNPRECEDENTED RATES, ADVERSELY IMPACTING INDIVIDUALS, FAMILIES, AND COMMUNITIES NATIONWIDE. SUBSTANTIVE EFFORTS HAVE BEEN MADE BY FEDERAL AND STATE AGENCIES, INCLUDING THE PROVIDERS CLINICAL SUPPORT SYSTEM (PCSS)-MAT. WHILE PCSS-MAT HAS MADE SIGNIFICANT PROGRESS OVER THE LAST DECADE IN PROVIDING INNOVATIVE TRAINING, MENTORING AND IMPLEMENTATION SUPPORT FOR PRESCRIBERS AND ALLIED HEALTH PROFESSIONALS IN THE USE OF EVIDENCE-BASED HARM REDUCTION, PREVENTION, TREATMENT, AND RECOVERY OF OPIOID USE DISORDERS (OUD), MORE IS NEEDED. IN RESPONSE, THE AMERICAN ACADEMY OF ADDICTION PSYCHIATRY (AAAP) PROPOSES IN THIS APPLICATION TO CONTINUE WORKING WITH THE LARGE COALITION OF NATIONAL PROFESSIONAL ORGANIZATIONS OF PCSS PARTNER ORGANIZATIONS AND THE PCSS STEERING COMMITTEE WHILE SIGNIFICANTLY BROADENING REPRESENTATION. OUR PARTNERS AND STEERING COMMITTEE INCLUDE EXPERTS IN ADDICTION PSYCHIATRY AND MEDICINE, SPECIALTY CARE PHYSICIANS, NURSES, PHYSICIAN ASSISTANTS, PHARMACISTS, AND DENTISTS. WE PROPOSE TO BUILD UPON THIS WORK TO INCLUDE SOCIAL WORKERS, COUNSELORS, AND THE RECOVERY COMMUNITY. FURTHER, GIVEN THAT THE MOST RECENT INCREASES IN OVERDOSES ARE SITUATED IN BLACK AND INDIGENOUS COMMUNITIES, WE WILL WORK TO BETTER MEET THE NEEDS OF HISTORICALLY MINORITIZED AND UNDER RESOURCED COMMUNITIES. BUILDING UPON CURRENT AND PRIOR WORK LED BY AAAP AND A COMMITTED CONSORTIUM OF PARTNERS REPRESENTING THE SPECTRUM OF INTERDISCIPLINARY HEALTH PROFESSIONS, THE OVERARCHING GOAL OF THIS APPLICATION IS TO INCREASE THE AVAILABILITY AND ACCESSIBILITY OF FDA-APPROVED MEDICATIONS FOR OUD (MOUD). THIS PCSS CONSORTIUM PROPOSES TO CONTINUE TO EXPAND AND DIVERSIFY ACTIVITIES TO MEET THE FOLLOWING OBJECTIVES: 1) CONTINUED EDUCATION (INCLUDING A FOCUS ON STIGMA REDUCTION); 2) TRAINING (INCLUDING NEW DEA REQUIRED TRAININGS); 3) KNOWLEDGE-BUILDING (INCLUDING THE BASICS OF OUD, POLY-SUBSTANCE USE, AND CO-OCCURRING MENTAL AND PHYSICAL DISORDERS); 4) CLINICAL MENTORSHIP; AND 5) IMPLEMENTATION SUPPORT (TO ADDRESS SYSTEMIC FACTORS THAT CAN FACILITATE OR IMPEDE TREATMENT DELIVERY, EXPANSION, AND SUSTAINABILITY). THIS WORK WILL BE AUGMENTED BY THE ADDICTION TECHNOLOGY TRANSFER CENTER (ATTC) AND THE PEER RECOVERY COE TO BETTER INTEGRATE RECOVERY INTO PCSS ACTIVITIES AND BROADENING REPRESENTATION OF OTHER SAMHSA TECHNICAL ASSISTANCE (TA) CENTERS TO BETTER SERVE RURAL AND HISTORICALLY MINORITIZED COMMUNITIES, INCLUDING RURAL OPIOID TECHNICAL ASSISTANCE (ROTA) AND THE AFRICAN AMERICAN BEHAVIORAL HEALTH CENTER OF EXCELLENCE (COE). PCSS ACTIVITIES WILL ALSO FOCUS ON EXPANDING MULTIDISCIPLINARY TEAM-BASED CARE, INCLUDING INVITING NEW PARTNERS FROM ALLIED HEALTH PROFESSIONAL FIELDS (E.G., NATIONAL ASSOCIATION OF SOCIAL WORKERS, NATIONAL ASSOCIATION OF ALCOHOL AND DRUG ADDICTION COUNSELORS, AFRICAN AMERICAN BEHAVIORAL HEALTH COE). FINALLY, AAAP WILL PROVIDE LEADERSHIP ON DIVERSITY, EQUITY AND INCLUSION (DEI) AND AWARENESS OF CULTURALLY RESPONSIVE TRAINING AND RESOURCES BY INCLUDING THEIR DEI DIRECTOR AND COMMUNITY ENGAGEMENT DIRECTOR TO THE PCSS STEERING COMMITTEE. THE OVERDOSE CRISIS, EXACERBATED BY COVID-19, HAS COMPELLED US TO RE-EVALUATE OUR APPROACH ON HOW BEST TO OVERCOME STIGMA, BE MORE PATIENT-CENTERED, AND PROVIDE CARE IN CULTURALLY RESPONSIVE WAYS. PCSS-MOUD IS STRUCTURED TO RESPOND RAPIDLY TO EMERGING ISSUES (E.G., CONTAMINANTS IN THE DRUG SUPPLY LIKE XYLAZINE), AS WELL AS MAXIMIZING FOUNDATIONAL TRAINING AND SUPPORT RESOURCES. THE GOAL OF PCSS-MOUD IS NOT TO DUPLICATE EFFORTS BUT TO STREAMLINE AND ENHANCE ACTIVITIES ACROSS THE COUNTRY BY COORDINATING AND COLLABORATING WITH OTHER SAMHSA-FUNDED TA PROGRAMS TO MORE EFFECTIVELY MEET THE NEEDS OF PEOPLE WITH OUD, ESPECIALLY THOSE EXPERIENCING HEALTH DISPARITIES. THIS CAN BE ACCOMPLISHED BY A CONCERTED AND FOCUSED EFFORT TO FILL GAPS IN THE AVAILABILITY OF PREVENTION, TREATMENT, RECOVERY AND HARM REDUCTION SERVICES AND WHERE WE CAN BUILD AND EXPAND MU
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.5m | 9/24/25 | ||
| Not listed | $0 | 4/14/25 | ||
| Not listed | $0 | 4/14/25 | ||
| Not listed | $1.0m | 9/19/24 | ||
| Not listed | $1.0m | 9/19/24 |